Switching to an AI following 2–3 years of initial adjuvant tamoxifen is an effective option for patients unable to begin treatment with an AI. This article evaluates the most up-to-date results ...

Tamoxifen is one of the most commonly used endocrine therapeutic agents for the treatment of estrogen receptor (ER)-positive breast cancer and is classified as a selective ER modulator, because it ...

Patients with ER-α66-positive breast cancer generally respond favorably to endocrine therapy; however, approximately 40% of such cancers do not respond to tamoxifen therapy. A novel variant of ...